Method of variability optimization in pharmacokinetic data analysis

被引:6
作者
Grabowski, Tomasz [1 ]
Jaroszewski, Jerzy Jan [2 ]
Piotrowski, Walerian [3 ]
Sasinowska-Motyl, Magorzta [4 ]
机构
[1] Polpharma Biol, PL-80172 Gdansk, Poland
[2] Univ Warmia & Mazury, Dept Pharmacol & Toxicol, Fac Vet Med, PL-10718 Olsztyn, Poland
[3] Inst Cardiol, Dept Epidemiol Cardiovasc Dis Prevent & Hlth Prom, Biostat Lab, Warsaw, Poland
[4] Med Univ Warsaw, Dept Pharmacodynam, PL-00927 Warsaw, Poland
关键词
Standard deviation; Sampling; Variability; Pharmacokinetics; HIGHLY VARIABLE DRUGS; STANDARD-DEVIATION; PHARMACODYNAMICS; ABSORPTION; COMPOUND;
D O I
10.1007/s13318-013-0145-x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
For many drugs administered per os, high variability in the concentration-time (C-T) values from first sampling to the phase of distribution may cause difficulty in pharmacokinetic analysis. Therefore, the aim of this study was to propose a method of transformation of C-T data, which would allow significantly reducing the standard deviation (SD) value of observed concentrations, without a statistically significant influence on the value of the mean for each sampling point in group. In the presented study, the lowest value of relative standard deviation of concentrations observed in the elimination phase and the value of precision of the used analytical method, were used to optimize the arithmetic, geometric means, median, and the value of SD obtained after single oral administration of itraconazole in human subjects. Non-compartmental modeling was used to estimate pharmacokinetic parameters. The analysis of SD pharmacokinetic parameters after C-T value optimization indicated more than twice the lower value of SD. After transforming the itraconazole data, lower variability of concentration data gives more selective pharmacokinetics profile in absorption and early distribution phase.
引用
收藏
页码:111 / 119
页数:9
相关论文
共 50 条
  • [31] Population pharmacokinetic analysis and dosing regimen optimization of meropenem in adult patients
    Li, Chonghua
    Kuti, Joseph L.
    Nightingale, Charles H.
    Nicolau, David P.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2006, 46 (10) : 1171 - 1178
  • [32] Population pharmacokinetic analysis and optimization of the experimental design for mizolastine solution in children
    Mentré, F
    Dubruc, C
    Thénot, JP
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2001, 28 (03) : 299 - 319
  • [33] Population Pharmacokinetic Analysis and Optimization of the Experimental Design for Mizolastine Solution in Children
    France Mentré
    Catherine Dubruc
    Jean-Paul Thénot
    Journal of Pharmacokinetics and Pharmacodynamics, 2001, 28 : 299 - 319
  • [34] Parameter Estimation and Reporting in Noncompartmental Analysis of Clinical Pharmacokinetic Data
    Noe, Dennis A.
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2020, 9 : S5 - S35
  • [35] Constructing Method Families Based on the Variability Analysis
    Kornyshova, Elena
    Ralyte, Jolita
    Deneckere, Rebecca
    2013 IEEE SEVENTH INTERNATIONAL CONFERENCE ON RESEARCH CHALLENGES IN INFORMATION SCIENCE (RCIS), 2013,
  • [36] Impact of drug transporter pharmacogenomics on pharmacokinetic and pharmacodynamic variability - considerations for drug development
    Lai, Yurong
    Varma, Manthena
    Feng, Bo
    Stephens, Joel Clay
    Kimoto, Emi
    El-Kattan, Ayman
    Ichikawa, Katsuomi
    Kikkawa, Hironori
    Ono, Chiho
    Suzuki, Akiyuki
    Suzuki, Misaki
    Yamamoto, Yuichi
    Tremaine, Larry
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2012, 8 (06) : 723 - 743
  • [37] Pharmacokinetic/pharmacodynamic considerations for the optimization of antimicrobial delivery in the critically ill
    Tsai, Danny
    Lipman, Jeffrey
    Roberts, Jason A.
    CURRENT OPINION IN CRITICAL CARE, 2015, 21 (05) : 412 - 420
  • [38] Factors affecting pharmacokinetic variability following doxorubicin and docetaxel-based therapy
    Rudek, MA
    Sparreboom, A
    Garrett-Mayer, ES
    Armstrong, DK
    Wolff, AC
    Verweij, J
    Baker, SD
    EUROPEAN JOURNAL OF CANCER, 2004, 40 (08) : 1170 - 1178
  • [39] Investigation of the impact of pharmacokinetic variability and uncertainty on risks predicted with a pharmacokinetic model for chloroform
    Allen, BC
    Covington, TR
    Clewell, HJ
    TOXICOLOGY, 1996, 111 (1-3) : 289 - 303
  • [40] The challenges of pharmacokinetic variability of first-line anti-TB drugs
    Daniel, Bella Devaleenal
    Ramachandran, Geetha
    Swaminathan, Soumya
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2017, 10 (01) : 47 - 58